SCHEMBL2092289

SCHEMBL2092289

CN(C([O])=O)c1cc(Cl)cc(Cl)c1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ATF1 P18846 1/20 0.43
NFKB1 P19838 1/20 0.43
TPMT P51580 1/20 0.39
FSCN1 Q16658 1/20 0.37
TSHR P16473 1/20 0.36
HTR3E A5X5Y0 1/20 0.36
HTR3B O95264 1/20 0.36
HTR3A P46098 1/20 0.36
HTR3D Q70Z44 1/20 0.36
HTR3C Q8WXA8 1/20 0.36
ALDH1A1 P00352 3/20 0.35
NOTUM Q6P988 1/20 0.35
TP53 P04637 1/20 0.35
P2RX1 P51575 1/20 0.34
RXRA P19793 1/20 0.34
RXRB P28702 1/20 0.34
RXRG P48443 1/20 0.34
GAA P10253 1/20 0.33
ACLY P53396 1/20 0.33
CLK1 P49759 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2092292 0.82 TPMT (0.44) ATF1NFKB1TPMTFSCN1TSHR
SCHEMBL12436239 0.80 ATF1 (0.42) ATF1NFKB1TPMTFSCN1TSHR
SCHEMBL2097577 0.80 HPGD (0.37) FSCN1TSHRALDH1A1P2RX1
SCHEMBL2096196 0.79 HTR3E (0.61) NFKB1TSHRHTR3EHTR3BHTR3A
SCHEMBL2095575 0.77 ALDH1A1 (0.48) FSCN1TSHRALDH1A1
SCHEMBL11394132 0.77 ATF1 (0.40) ATF1NFKB1TPMTFSCN1HTR3E
SCHEMBL2091610 0.77 ATF1 (0.40) ATF1NFKB1TPMTTSHRALDH1A1
SCHEMBL2089844 0.76 FSCN1 (0.44) TPMTFSCN1TSHRALDH1A1GAA
SCHEMBL2091609 0.75 ATF1 (0.39) ATF1NFKB1TPMTFSCN1HTR3E
SCHEMBL22289622 0.75 GABRP (0.46) ATF1NFKB1TPMTHTR3EHTR3B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8163753-B2 2-(4-(4-(4-chlorophenyl)oxazol-2-yl)phenoxymethyl)-2-methyl-6-nitro-2,3-dihydroimidazo[2,1-b]oxazole; bactericide; excellent bactericidal action against Mycobacterium tuberculosis, multi-drug-resistant Mycobacterium tuberculosis, and atypical acid-fast bacteria OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2012-04-24 US disclosed
EP-1678185-B1 2,3-DIHYDRO-6-NITROIMIDAZO [2,1-B] OXAZOLE COMPOUNDS FOR THE TREATMENT OF TUBERCULOSIS OTSUKA PHARMA CO LTD (JP) 2008-10-08 EP disclosed
US-20080119478-A1 2,3-Dihydro-6-Nitroimidazo (2,1-b) Oxazole Compounds for the Treatment of Tuberculosis OTSUKA PHAMACEUTICAL CO., LTD. (JP) 2008-05-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080119478-A1 2,3-Dihydro-6-Nitroimidazo (2,1-b) Oxazole Compounds for the Treatment of Tuberculosis NR2C2, NR0B2, NR4A2 ATF1 2139/4885NFKB1 1248/4885TPMT 2767/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.